Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

被引：10

作者：

Pipe, Steven W. ^{[1
]}

Collins, Peter ^{[2
]}

Dhalluin, Christophe ^{[3
]}

Kenet, Gili ^{[4
,5
]}

Schmitt, Christophe ^{[3
]}

Buri, Muriel ^{[3
]}

Jimenez-Yuste, Victor ^{[6
]}

Peyvandi, Flora ^{[7
,8
,9
]}

Young, Guy ^{[10
]}

Oldenburg, Johannes ^{[11
]}

Mancuso, Maria Elisa ^{[12
]}

Kiialainen, Anna ^{[3
]}

Chang, Tiffany ^{[13
]}

Lehle, Michaela ^{[3
]}

Fijnvandraat, Karin ^{[14
]}

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Cardiff Univ, Sch Med, Cardiff, Wales

[3] F Hoffmann La Roche Ltd, Basel, Switzerland

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain

[7] Fdn IRCCS CaGranda Osped Maggiore Policlin, Angelo Bianchi Bon Hemophilia, Milan, Italy

[8] Thrombosis Ctr, Milan, Italy

[9] Univ Milan, Milan, Italy

[10] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA

[11] Univ Bonn, Bonn, Germany

[12] IRCCS Humanitas Res Hosp, Rozzano, Italy

[13] Spark Therapeut Inc, San Francisco, CA USA

[14] Univ Amsterdam, Amsterdam, Netherlands

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
Pipe, Steven
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Niggli, Markus
Fijnvandraat, Karin
BLOOD, 2023, 142
[2] EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Niggli, Markus
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 99 - 99
[3] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
Pipe, S. W.
Collins, P.
Dhalluin, C.
Kenet, G.
Schmitt, C.
Buri, M.
Jimenez-Yuste, V.
Peyvandi, F.
Young, G.
Oldenburg, J.
Mancuso, M. E.
Kavakli, K.
Kiialainen, A.
Niggli, M.
Chang, T.
Lehle, M.
Fijnvandraat, K.
HAEMOPHILIA, 2024, 30 : 24 - 25
[4] EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7
Pipe, Steven
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
ElisaMancuso, Maria
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
PEDIATRIC BLOOD & CANCER, 2023, 70 : S7 - S7
[5] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH MILD OR MODERATE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: RESULTS FROM THE INTERIM ANALYSIS OF THE HAVEN 6 STUDY
Negrier, C.
Mahlangu, J.
Lehle, M.
Chowdary, P.
Catalani, O.
Jimenez-Yuste, V.
Beckermann, B. M.
Schmitt, C.
Hermans, C.
Ventriglia, G.
Windyga, J.
Kiialainen, A.
d'Oiron, R.
Moorehead, P.
Teodoro, V.
Shapiro, A.
Oldenburg, J.
HAEMOPHILIA, 2022, 28 : 20 - 21
[6] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Escobar, Miguel
Agrawal, Neha
Chatterjee, Sagnik
Bhattacharya, Swastik
Caicedo, Jorge
Bullano, Michael
Schultz, Robert G.
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
[7] FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A
Young, Guy
Eakle, Katherine
Lim, Elise
Wang, Michael
BLOOD, 2024, 144 : 2589 - 2590
[8] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
Escobar, Miguel
Agrawal, Neha
Chatterjee, Sagnik
Bhattacharya, Swastik
Caicedo, Jorge
Bullano, Michael
Schultz, Bob G. G.
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
[9] Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
Callaghan, Michael
Trzaskoma, Benjamin
Ko, Richard H.
Lee, Lucy
Patel, Anisha M.
Tzeng, Eunice
Shah, Michelle Lynn
Chang, Tiffany Y.
Niggli, Markus
Dhalluin, Christophe
Mahlangu, Johnny
BLOOD, 2019, 134
[10] Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A
Shima, Midori
JOURNAL OF PEDIATRICS, 2017, 190 : 289 - 289

← 1 2 3 4 5 →